We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Aliskiren and Muscle Sympathetic Nerve Activity (MSNA)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2008 by UMC Utrecht.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: July 21, 2008
Last Update Posted: January 14, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
UMC Utrecht
The central hypothesis of this project is that Aliskiren causes a substantial decrease in MSNA in hypertensive patients with CKD.

Condition Intervention Phase
Chronic Kidney Disease Hypertension Muscle Sympathetic Nerve Activity Drug: Aliskiren Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by UMC Utrecht:

Primary Outcome Measures:
  • Normalisation of muscle sympathetic nerve activity [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Blood pressure and Blood tests [ Time Frame: 1 year ]

Estimated Enrollment: 30
Study Start Date: July 2008
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1
Patients receive Aliskiren 300mg for 6 weeks
Drug: Aliskiren
Aliskiren 300mg per day for 6 weeks
Other Name: Rasilez 300mg per day
No Intervention: Group 2
4 weeks no antihypertensive medication

Detailed Description:
Cardiovascular (CV) morbidity and mortality are frequently occurring problems in chronic kidney disease (CKD) patients. Apart from the so called traditional risk factors, also risk factors more or less specific to CKD contribute in the pathogenesis of these problems. There is strong evidence that the sympathetic hyperactivity, which often characterizes CKD, is one such factor. Previously, we have shown that angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) reduce but not normalize this sympathetic hyperactivity. We re-analysed the cohort of patients who were investigated in the past and subsequently treated according to present guidelines. The results show that, despite of treatment, the unfavourable relation between sympathetic hyperactivity and clinical outcome still exits. This might mean that treatment is insufficient. In present study, we want to study the effect of Aliskiren 300mg on sympathetic nerve activity.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with stable chronic kidney disease and hypertension: i.e. using antihypertensive drugs and/or blood pressure > 145/90 mmHg when off medication.
  • Patients on ACE inhibitor or ARB

Exclusion Criteria:

  • Patients with diabetes mellitus
  • Patients on renal replacement therapy
  • Pregnant patients Using of antihypertensive which cannot be stopped
  • Patients on immunosuppressive therapy and active nephrotic syndrome
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00719316

Contact: Laima Siddiqi, MD + 31 88 755 7329 l.siddiqi@umcutrecht.nl

University Medical Center utrecht Recruiting
Utrecht, Netherlands, 3584CX
Principal Investigator: Laima Siddiqi, MD         
Sponsors and Collaborators
UMC Utrecht
Principal Investigator: P. J. Blankestijn, MD, PhD UMC Utrecht
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. P. J. Blankestijn, UMC Utrecht
ClinicalTrials.gov Identifier: NCT00719316     History of Changes
Other Study ID Numbers: NL19926.041.07
First Submitted: July 17, 2008
First Posted: July 21, 2008
Last Update Posted: January 14, 2010
Last Verified: July 2008

Keywords provided by UMC Utrecht:
Renin inhibitor
ACE inhibitor or ARB
Chronic Kidney Disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Vascular Diseases
Cardiovascular Diseases
Urologic Diseases
Renal Insufficiency